Sarecycline - Paratek Pharmaceuticals

Drug Profile

Sarecycline - Paratek Pharmaceuticals

Alternative Names: P 0005672; P 005672; Seysara; WC-3035

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Actavis; Allergan
  • Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acne vulgaris
  • Phase II Rosacea

Most Recent Events

  • 20 Dec 2017 Allergan expects the Prescription Drug User Fee Act date for sarecycline to be in in the second half of 2018
  • 31 Oct 2017 Preregistration for Acne vulgaris (In adolescents, In children, In adults) in USA (PO)
  • 27 Mar 2017 Allergan plans to file an NDA with the US FDA for Acne vulgaris in the second-half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top